Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Histologically confirmed diagnosis of non-squamous NSCLC; Stage ⅢA-ⅢB(not suitable for surgery) or stage Ⅳ(only single-site single transfer ); * Untreated patients, or who completed ≤ 2 cycles of first-line chemotherapy (chemotherapy regimen: paclitaxel, docetaxel + cisplatin) within the previous month; * Patients with tumor EGFR mutation positive (exon 19 deletion mutation or exon 21 L858R substitution mutation); * Patients must be informed of the investigational nature of the study and must sign an informed consent form; * Presence of at least one measurable/evaluable according to RECIST criteria. * ECOG performance Status 0-2 ; * Patients must have a life expectancy \> 12 weeks; * Patients with laboratory values as follows:WBC\>4.0 x 109/L; ANC≥1.5 x 109/L; PLT≥100 x 109/L; HGB≥10 g/dL; CR≤1.5 x ULN; TBIL\<1.5 x ULN; AST and ALT≤1.5 x ULN; LDH≤1.5 x ULN; AKP≤5 x ULN; * FEV 1≥1.0L and \>50% Corresponding normal values; * Patient candidate to standard platinum-based chemotherapy; * Patients must be nonpregnant and non-lactating.Patients of childbearing potential must implement an effective method of contraception during the study. All female Patients, except those who are postmenopausal or surgically sterilized, must have a negative pre-study serum or urine pregnancy test. Exclusion Criteria: * Any evidence of clinically active interstitial lung disease; * Diagnosis of any other malignancy during the last 5 years, except for in situ carcinoma of cervix uterine and squamous cell carcinoma of the skin； * Pregnancy or lactating； * Serious concomitant infection; * MI within preceding 6 months or symptomatic heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmia; * As judged by the investigator, any evidence of severe or uncontrolled systemic disease (eg, unstable or uncompensated respiratory, cardiac, hepatic, or renal disease); * Patients who are not suitable to participate in the trial according to researchers.